ANNEXON INC (ANNX) Stock Price, Quote, News and Overview
NASDAQ:ANNX - Nasdaq - US03589W1027 - Common Stock - Currency: USD
ANNX Quote, Performance and Key Statistics
2.59
-0.01 (-0.38%)
The current stock price of ANNX is 2.59 USD. In the past month the price increased by 61.88%. In the past year, price decreased by -53.91%.
ANNX Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 18.42 | 334.13B | ||
| AMGN | AMGEN INC | 13.97 | 155.93B | ||
| GILD | GILEAD SCIENCES INC | 14.6 | 140.56B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | N/A | 114.57B | ||
| REGN | REGENERON PHARMACEUTICALS | 11.68 | 55.89B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 39.64B | ||
| ARGX | ARGENX SE - ADR | 101.5 | 35.64B | ||
| ONC | BEONE MEDICINES LTD-ADR | 6.75 | 28.54B | ||
| BNTX | BIONTECH SE-ADR | N/A | 26.20B | ||
| NTRA | NATERA INC | N/A | 22.42B | ||
| BIIB | BIOGEN INC | 8.48 | 19.66B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 16.01B |
Related stock screener links
About ANNX
Company Profile
Annexon, Inc. is a clinical-stage biopharmaceutical company, which develops a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, eye and brain. The company is headquartered in Brisbane California, California and currently employs 100 full-time employees. The company went IPO on 2020-07-24. The company identifies and characterizes the role of the classical complement pathway in three therapeutic areas: autoimmune, neurodegeneration and ophthalmology, using its proprietary platform. Its lead candidate, ANX005, an investigational, full-length monoclonal antibody (mAb), is formulated for intravenous administration as the potential first targeted treatment for patients with Guillain-Barre Syndrome (GBS). The company is advancing ANX1502, a novel small-molecule inhibitor of classical complement designed for oral administration in a range of chronic autoimmune diseases. The company is also advancing ANX007, designed to block C1q locally in the eye, to provide complete protection against excess classical complement activity and the loss of photoreceptor neurons.
Company Info
ANNEXON INC
1400 Sierra Point Parkway, Bldg C Suite 200
Brisbane California CALIFORNIA 94080 US
CEO: Douglas Love Esq.
Employees: 100
Phone: 16508225500
ANNEXON INC / ANNX FAQ
What is the stock price of ANNEXON INC today?
The current stock price of ANNX is 2.59 USD. The price decreased by -0.38% in the last trading session.
What is the ticker symbol for ANNEXON INC stock?
The exchange symbol of ANNEXON INC is ANNX and it is listed on the Nasdaq exchange.
On which exchange is ANNX stock listed?
ANNX stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for ANNEXON INC stock?
14 analysts have analysed ANNX and the average price target is 11.83 USD. This implies a price increase of 356.83% is expected in the next year compared to the current price of 2.59. Check the ANNEXON INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is ANNEXON INC worth?
ANNEXON INC (ANNX) has a market capitalization of 284.15M USD. This makes ANNX a Micro Cap stock.
How many employees does ANNEXON INC have?
ANNEXON INC (ANNX) currently has 100 employees.
What are the support and resistance levels for ANNEXON INC (ANNX) stock?
ANNEXON INC (ANNX) has a support level at 1.82 and a resistance level at 2.61. Check the full technical report for a detailed analysis of ANNX support and resistance levels.
Should I buy ANNEXON INC (ANNX) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of ANNX, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of ANNX, evaluating the profitability, health, valuation and growth aspects
- ANNEXON INC (ANNX) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- ANNEXON INC (ANNX) Sales and EPS estimates to see what analysts future expectations are.
- ANNEXON INC (ANNX) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- ANNEXON INC (ANNX) Insider and Institutional Ownership to learn about the owners and their transactions.
- ANNEXON INC (ANNX) Stock Chart to make your own analysis
- ANNEXON INC (ANNX) Latest news and press-releases to stay up to date.
Does ANNEXON INC (ANNX) stock pay dividends?
ANNX does not pay a dividend.
When does ANNEXON INC (ANNX) report earnings?
ANNEXON INC (ANNX) will report earnings on 2025-08-11.
What is the Price/Earnings (PE) ratio of ANNEXON INC (ANNX)?
ANNEXON INC (ANNX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.18).
What is the Short Interest ratio of ANNEXON INC (ANNX) stock?
The outstanding short interest for ANNEXON INC (ANNX) is 9.96% of its float. Check the ownership tab for more information on the ANNX short interest.
ANNX Technical Analysis
ChartMill assigns a technical rating of 4 / 10 to ANNX. When comparing the yearly performance of all stocks, ANNX is a bad performer in the overall market: 90.02% of all stocks are doing better.
ANNX Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to ANNX. No worries on liquidiy or solvency for ANNX as it has an excellent financial health rating, but there are worries on the profitability.
ANNX Financial Highlights
Over the last trailing twelve months ANNX reported a non-GAAP Earnings per Share(EPS) of -1.18. The EPS increased by 19.73% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -55.24% | ||
| ROE | -68.66% | ||
| Debt/Equity | 0 |
ANNX Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 84% to ANNX. The Buy consensus is the average rating of analysts ratings from 14 analysts.